Ferroptosis: A therapeutic opportunity of inflammatory bowel disease

Ye, Yulin; Liu, Limin; Jing, Yang; Yao, Shuangzhe; Yang, Mo; Dai, Xin; Piao, Meiyu; Xu, Xin; Feng, Zelin; Wang, Xiaoli; Liu, Yifei; Miao, Junming; Gao, Xingjie; Yu, Qingxiang; Cao, Xiaocang

doi:10.1097/cm9.0000000000002998

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ferroptosis, a new type of cell death, involves unique biological processes and pathophysiological characteristics and is accompanied primarily by iron accumulation and lipid peroxidation [10][11][12] . Current evidence indicates that ferroptosis inhibition can signi cantly mitigate the clinical features associated with gastrointestinal diseases, including IBD, suggesting that ferroptosis is a promising novel therapeutic target [13][14][15] . Our prior research has revealed that different macrophage subtypes exhibit varying sensitivities to reactive oxygen species, a pivotal component of ferroptosis 16 .…”

Section: Introductionmentioning

confidence: 99%

Enhancing the therapeutic effect of infliximab by inhibiting ferroptosis of M2 macrophages in experimental colitis

Feng,

Ye,

Liu

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Objective Drug combination presents a promising approach to surpassing the current efficacy limitations of biological agents in treating inflammatory bowel disease (IBD). Currently, ferroptosis has emerged as a novel therapeutic target for IBD. Therefore, combining ferroptosis inhibitors with biologics may provide a new therapeutic strategy to break the therapeutic ceiling of IBD treatment. Thus, this study investigated whether ferroptosis inhibitors could enhance infliximab (IFX) efficacy on IBD. Methods Immunofluorescence was used to analyze M2 macrophages in human colon specimens pre- and post-IFX treatment. The effect of IFX on ferroptosis of M1 and M2 macrophages was assessed on RAW264.7 in vitro. Moreover, a DSS-induced colitis mouse model was employed to evaluate the impact of ferroptosis inhibitors on IFX efficacy in vivo. Results Although M2 macrophages were increased in patients who responded to IFX treatment, there was no concurrent increase in non-responders which suggested that the efficacy of IFX was closely related to M2 macrophage. Notably, IFX enhanced ferroptosis in M1 and M2 macrophages in vitro, while M2 macrophages were more sensitive to ferroptosis than M1 macrophages. Finally, the ferroptosis inhibitor deferoxamine enhanced IFX efficacy by significantly alleviating mucosa ferroptosis in experimental colitis mice and also had a protective effect on M2 macrophages undergoing IFX. Conclusions The current results suggested that ferroptosis inhibitors could enhance the therapeutic efficacy of IFX by rescuing M2 macrophages from ferroptosis, thereby offering a new strategy for overcoming the current therapeutic ceiling of IBD biologic therapy.

show abstract